Probity Advisors Inc. Acquires 311 Shares of Edwards Lifesciences Corporation $EW

Probity Advisors Inc. raised its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 6.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,154 shares of the medical research company’s stock after buying an additional 311 shares during the quarter. Probity Advisors Inc.’s holdings in Edwards Lifesciences were worth $403,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Jennison Associates LLC grew its position in shares of Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after buying an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Edwards Lifesciences by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock worth $491,673,000 after buying an additional 264,311 shares in the last quarter. Nuveen LLC bought a new position in Edwards Lifesciences in the first quarter worth about $330,881,000. Invesco Ltd. raised its stake in Edwards Lifesciences by 2.6% in the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after buying an additional 107,241 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Edwards Lifesciences by 5.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after buying an additional 198,882 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $76.03 on Wednesday. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.00. The company has a 50 day simple moving average of $77.46 and a two-hundred day simple moving average of $76.25. The company has a market capitalization of $44.64 billion, a price-to-earnings ratio of 10.94, a P/E/G ratio of 3.61 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the company posted $0.70 earnings per share. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research reports. The Goldman Sachs Group reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Stifel Nicolaus set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. Barclays increased their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Wells Fargo & Company increased their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Finally, William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.